Larissa Warneck-Silvestrin

3 weeks ago | insideprecisionmedicine.com | Larissa Warneck-Silvestrin |Larissa Warneck

Scientists at the Gray Faculty of Medical and Health Sciences at Tel Aviv University in Israel have discovered that neutrophils, a type of immune cell, play an important role in breast cancer tumor progression. These findings, say the researchers, could make neutrophils important drug targets and biomarkers for advanced breast cancer. In 2022, there were an estimated 2.3 million new breast cancer cases, and approximately 670,000 deaths resulted from female breast cancer.

1 month ago | insideprecisionmedicine.com | Larissa Warneck-Silvestrin |Larissa Warneck

Researchers at the Sydney Brenner Institute for Molecular Bioscience (SBIMB) at the University of the Witwatersrand in Johannesburg, South Africa, have discovered two genetic variants that can be linked to breast cancer in black South African women.

1 month ago | insideprecisionmedicine.com | Larissa Warneck-Silvestrin |Larissa Warneck

GLP-1RAs, first-generation weight-loss medications, such as liraglutide—known by the brand names Victoza and Saxenda—and exenatide—marketed under the names Byetta and Bydureon—seem to have anti-cancer benefits beyond weight loss, compared to weight loss surgery. This new study was led by researchers of Clalit Health Services in Tel Aviv, Israel, and the Hasharon Hospital, Rabin Medical Center in Petah Tikva, Israel.

2 months ago | insideprecisionmedicine.com | Larissa Warneck-Silvestrin |Kathy Vuksanaj

With the advent of next-generation sequencing (NGS) technologies just over a decade ago, genomic information became available not only in labs, but also in clinical practice. Today, genomic testing is starting to play an important role in cancer patient care. Knowing the genetic makeup of a tumor can help oncologists determine the best therapeutic options for a patient, making genomic testing a growing part of precision medicine.

Jan 30, 2025 | biopharma-reporter.com | Larissa Warneck-Silvestrin

The U.S. biotech company Atalanta Therapeutics announced this week that it has raised $97 million in an oversubscribed Series B financing round led by the Swedish investment organization EQT Life Sciences and co-led by Sanofi Ventures and with participation from others. The financing will support the Phase 1 clinical development of two of Atalanta’s investigational RNA interference (RNAi) therapies for a specific form of epilepsy known as KCTN1-related epilepsy and Huntington’s disease.